

# Carlos A Zarate Jr

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9308699/carlos-a-zarate-jr-publications-by-year.pdf>

**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

249 papers	21,317 citations	73 h-index	142 g-index
264 ext. papers	24,947 ext. citations	6.3 avg, IF	7.02 L-index

#	Paper	IF	Citations
249	Lithium treatment of Bipolar disorder in adults: A systematic review of randomized trials and meta-analyses.. <i>European Neuropsychopharmacology</i> , <b>2022</b> , 54, 100-115	1.2	6
248	The relationship between the HDRS insomnia items and polysomnographic (PSG) measures in individuals with treatment-resistant depression.. <i>Journal of Psychiatric Research</i> , <b>2022</b> , 148, 27-33	5.2	1
247	AuthorsSReply to Pappagallo et al.: Comment on "Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status".. <i>CNS Drugs</i> , <b>2022</b> , 36, 205	6.7	0
246	Ketamine for Depression: Advances in Clinical Treatment, Rapid Antidepressant Mechanisms of Action, and a Contrast with Serotonergic Psychedelics.. <i>Current Topics in Behavioral Neurosciences</i> , <b>2022</b> , 1	3.4	
245	A Predictive Coding Framework for Understanding Major Depression.. <i>Frontiers in Human Neuroscience</i> , <b>2022</b> , 16, 787495	3.3	0
244	Ketamine treatment for depression: a review.. <i>Discover Mental Health</i> , <b>2022</b> , 2, 9		4
243	Effects of stress on endophenotypes of suicide across species: A role for ketamine in risk mitigation. <i>Neurobiology of Stress</i> , <b>2022</b> , 100450	7.6	0
242	Comparative metabolomic analysis in plasma and cerebrospinal fluid of humans and in plasma and brain of mice following antidepressant-dose ketamine administration.. <i>Translational Psychiatry</i> , <b>2022</b> , 12, 179	8.6	1
241	The kynurenine pathway and bipolar disorder: intersection of the monoaminergic and glutamatergic systems and immune response. <i>Molecular Psychiatry</i> , <b>2021</b> , 26, 4085-4095	15.1	24
240	The mental health impact of contact with COVID-19 patients on healthcare workers in the United States.. <i>Psychiatry Research</i> , <b>2021</b> , 308, 114359	9.9	0
239	Ketamine modulates fronto-striatal circuitry in depressed and healthy individuals. <i>Molecular Psychiatry</i> , <b>2021</b> , 26, 3292-3301	15.1	16
238	Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications. <i>Pharmacological Reviews</i> , <b>2021</b> , 73, 763-791	22.5	17
237	Commentary on the Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder. <i>Canadian Journal of Psychiatry</i> , <b>2021</b> , 66, 537-539	4.8	1
236	Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability. <i>Molecular Psychiatry</i> , <b>2021</b> ,	15.1	32
235	Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status. <i>CNS Drugs</i> , <b>2021</b> , 35, 527-543	6.7	23
234	Translating the immediate effects of S-Ketamine using hippocampal subfield analysis in healthy subjects-results of a randomized controlled trial. <i>Translational Psychiatry</i> , <b>2021</b> , 11, 200	8.6	4
233	Ketamine for Bipolar Depression: A Systematic Review. <i>International Journal of Neuropsychopharmacology</i> , <b>2021</b> , 24, 535-541	5.8	3

232	Reply to: "Letter to the Editor: Are ketamine-induced subjective bodily experiences associated with antidepressant effects? A sensation of floating and a sensation of Lightness are not the same - A comment on Acevedo-Diaz et al." (Jpsychiatrres-D-21-00121). <i>Journal of Psychiatric Research</i> , <b>2021</b> , 137, 409-410	5.2	
231	Fine-tuning neural excitation/inhibition for tailored ketamine use in treatment-resistant depression. <i>Translational Psychiatry</i> , <b>2021</b> , 11, 335	8.6	3
230	Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. <i>American Journal of Psychiatry</i> , <b>2021</b> , 178, 383-399	11.9	67
229	Ketamine and Attentional Bias Toward Emotional Faces: Dynamic Causal Modeling of Magnetoencephalographic Connectivity in Treatment-Resistant Depression. <i>Frontiers in Psychiatry</i> , <b>2021</b> , 12, 673159	5	1
228	Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis. <i>Journal of Affective Disorders</i> , <b>2021</b> , 278, 542-555	6.6	58
227	Ketamine Alters Electrophysiological Responses to Emotional Faces in Major Depressive Disorder. <i>Journal of Affective Disorders</i> , <b>2021</b> , 279, 239-249	6.6	2
226	Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants. <i>International Journal of Neuropsychopharmacology</i> , <b>2021</b> , 24, 8-21	5.8	26
225	Treatment of depression with ketamine does not change plasma levels of brain-derived neurotrophic factor or vascular endothelial growth factor. <i>Journal of Affective Disorders</i> , <b>2021</b> , 280, 136-139	6.6	8
224	New Methods for Assessing Rapid Changes in Suicide Risk. <i>Frontiers in Psychiatry</i> , <b>2021</b> , 12, 598434	5	11
223	Overview of ketamine for major depression: efficacy and effectiveness <b>2021</b> , 117-129		1
222	Clinical trials for rapid changes in suicidal ideation: Lessons from ketamine. <i>Suicide and Life-Threatening Behavior</i> , <b>2021</b> , 51, 27-35	3.9	2
221	Response to commentary on the comparative efficacy of esketamine vs. ketamine meta-analysis: Putting the cart before the horse?. <i>Journal of Affective Disorders</i> , <b>2021</b> , 282, 258-260	6.6	2
220	Evaluation of the safety, tolerability and pharmacokinetic profiles of TP0473292 (TS-161), a prodrug of a novel orthosteric mGlu2/3 receptor antagonist TP0178894, in healthy subjects and its antidepressant-like effects in rodents. <i>International Journal of Neuropsychopharmacology</i> , <b>2021</b> ,	5.8	2
219	Glutamate modulators and beyond: A neuroscience revolution in the making. <i>European Neuropsychopharmacology</i> , <b>2021</b> , 54, 72-72	1.2	0
218	A comparison of the pharmacokinetics and NMDAR antagonism-associated neurotoxicity of ketamine, (2R,6R)-hydroxynorketamine and MK-801. <i>Neurotoxicology and Teratology</i> , <b>2021</b> , 87, 106993	3.9	4
217	A wake-up call: Sleep physiology and related translational discrepancies in studies of rapid-acting antidepressants. <i>Progress in Neurobiology</i> , <b>2021</b> , 206, 102140	10.9	1
216	Sex-dependent metabolism of ketamine and ()-hydroxynorketamine in mice and humans.. <i>Journal of Psychopharmacology</i> , <b>2021</b> , 2698811211064922	4.6	0
215	Neurobiological biomarkers of response to ketamine. <i>Advances in Pharmacology</i> , <b>2020</b> , 89, 195-235	5.7	11

214	Electrophysiological biomarkers of antidepressant response to ketamine in treatment-resistant depression: Gamma power and long-term potentiation. <i>Pharmacology Biochemistry and Behavior</i> , <b>2020</b> , 189, 172856	3.9	17
213	Not So Fast: Recent Successes and Failures in Treating Depression. <i>Journal of Clinical Psychiatry</i> , <b>2020</b> , 81,	4.6	2
212	Ketamine: a new chapter in antidepressant development. <i>Revista Brasileira De Psiquiatria</i> , <b>2020</b> , 42, 581-582		
211	The role of dissociation in ketamine's antidepressant effects. <i>Nature Communications</i> , <b>2020</b> , 11, 6431	17.4	27
210	Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression. <i>Journal of Affective Disorders</i> , <b>2020</b> , 263, 568-575	6.6	36
209	Magnetoencephalographic Correlates of Suicidal Ideation in Major Depression. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , <b>2020</b> , 5, 354-363	3.4	6
208	Development of the Ketamine Side Effect Tool (KSET). <i>Journal of Affective Disorders</i> , <b>2020</b> , 266, 615-620	6.6	12
207	Can fMRI predict treatment response to ketamine? Data from three randomized trials of individuals with treatment-resistant depression. <i>Journal of Psychiatric Research</i> , <b>2020</b> , 130, 280-285	5.2	11
206	Prognosis and Improved Outcomes in Major Depression: A Review. <i>Focus (American Psychiatric Publishing)</i> , <b>2020</b> , 18, 220-235	1.1	7
205	A Randomized Trial of the N-Methyl-D-Aspartate Receptor Glycine Site Antagonist Prodrug 4-Chlorokynurenine in Treatment-Resistant Depression. <i>International Journal of Neuropsychopharmacology</i> , <b>2020</b> , 23, 417-425	5.8	20
204	Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression. <i>Neuropsychopharmacology</i> , <b>2020</b> , 45, 1398-1404	8.7	20
203	Ketamine-Induced Glutamatergic Mechanisms of Sleep and Wakefulness: Insights for Developing Novel Treatments for Disturbed Sleep and Mood. <i>Handbook of Experimental Pharmacology</i> , <b>2019</b> , 253, 337-358	3.2	24
202	Impact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant. <i>Neuropsychopharmacology</i> , <b>2019</b> , 44, 1233-1238	8.7	20
201	Mapping anticipatory anhedonia: an fMRI study. <i>Brain Imaging and Behavior</i> , <b>2019</b> , 13, 1624-1634	4.1	4
200	Effects of Ketamine on Brain Activity During Emotional Processing: Differential Findings in Depressed Versus Healthy Control Participants. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , <b>2019</b> , 4, 610-618	3.4	17
199	(R)-hydroxynorketamine exerts mGlu receptor-dependent antidepressant actions. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2019</b> , 116, 6441-6450	11.5	73
198	Prognosis and improved outcomes in major depression: a review. <i>Translational Psychiatry</i> , <b>2019</b> , 9, 127	8.6	127
197	Antidepressant-relevant concentrations of the ketamine metabolite (2,6)-hydroxynorketamine do not block NMDA receptor function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2019</b> , 116, 5160-5169	11.5	77

196	The influence of ketamine on drug discovery in depression. <i>Drug Discovery Today</i> , <b>2019</b> , 24, 2033-2043	8.8	35
195	The Classification of Depression: Embracing Phenotypic Heterogeneity in the Era of the RDoC <b>2019</b> , 1-8		
194	Ketamine for Treatment-Resistant Mood Disorders. <i>Focus (American Psychiatric Publishing)</i> , <b>2019</b> , 17, 8-12	1.1	12
193	Research on the pathophysiology, treatment, and prevention of suicide: practical and ethical issues. <i>BMC Psychiatry</i> , <b>2019</b> , 19, 332	4.2	15
192	Neurophysiological Changes Associated with Antidepressant Response to Ketamine Not Observed in a Negative Trial of Scopolamine in Major Depressive Disorder. <i>International Journal of Neuropsychopharmacology</i> , <b>2019</b> , 22, 10-18	5.8	20
191	Synaptic potentiation and rapid antidepressant response to ketamine in treatment-resistant major depression: A replication study. <i>Psychiatry Research - Neuroimaging</i> , <b>2019</b> , 283, 64-66	2.9	19
190	Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments. <i>International Journal of Neuropsychopharmacology</i> , <b>2019</b> , 22, 119-135	5.8	70
189	Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of ()-hydroxynorketamine. <i>Journal of Psychopharmacology</i> , <b>2019</b> , 33, 12-24	4.6	21
188	Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants. <i>Annual Review of Pharmacology and Toxicology</i> , <b>2019</b> , 59, 213-236	17.9	59
187	Disentangling the association of depression on the anti-fatigue effects of ketamine. <i>Journal of Affective Disorders</i> , <b>2019</b> , 244, 42-45	6.6	6
186	Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects. <i>Molecular Psychiatry</i> , <b>2019</b> , 24, 1040-1052	15.1	123
185	Default Mode Connectivity in Major Depressive Disorder Measured Up to 10 Days After Ketamine Administration. <i>Biological Psychiatry</i> , <b>2018</b> , 84, 582-590	7.9	82
184	Glutamatergic Modulators in Depression. <i>Harvard Review of Psychiatry</i> , <b>2018</b> , 26, 307-319	4.1	43
183	Convergent Mechanisms Underlying Rapid Antidepressant Action. <i>CNS Drugs</i> , <b>2018</b> , 32, 197-227	6.7	92
182	Clinical Trial of the Potassium Channel Activator Diazoxide for Major Depressive Disorder Halted Due to Intolerability. <i>Journal of Clinical Psychopharmacology</i> , <b>2018</b> , 38, 243-246	1.7	3
181	7T H-MRS in major depressive disorder: a Ketamine Treatment Study. <i>Neuropsychopharmacology</i> , <b>2018</b> , 43, 1908-1914	8.7	21
180	Glutamatergic Signaling Drives Ketamine-Mediated Response in Depression: Evidence from Dynamic Causal Modeling. <i>International Journal of Neuropsychopharmacology</i> , <b>2018</b> , 21, 740-747	5.8	34
179	Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression. <i>Journal of Affective Disorders</i> , <b>2018</b> , 232, 310-315	6.6	52

178	Parsing the heterogeneity of depression: An exploratory factor analysis across commonly used depression rating scales. <i>Journal of Affective Disorders</i> , <b>2018</b> , 231, 51-57	6.6	38
177	The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. <i>American Journal of Psychiatry</i> , <b>2018</b> , 175, 150-158	11.9	311
176	Ketamine normalizes brain activity during emotionally valenced attentional processing in depression. <i>NeuroImage: Clinical</i> , <b>2018</b> , 20, 92-101	5.3	33
175	Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects. <i>Psychopharmacology</i> , <b>2018</b> , 235, 3017-3030	4.7	53
174	Characterizing the course of suicidal ideation response to ketamine. <i>Journal of Affective Disorders</i> , <b>2018</b> , 241, 86-93	6.6	30
173	Are 24-hour motor activity patterns associated with continued rapid response to ketamine?. <i>Neuropsychiatric Disease and Treatment</i> , <b>2018</b> , 14, 2739-2748	3.1	12
172	Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression. <i>Translational Psychiatry</i> , <b>2018</b> , 8, 280	8.6	18
171	Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms. <i>Pharmacological Reviews</i> , <b>2018</b> , 70, 621-660	22.5	395
170	New targets for rapid antidepressant action. <i>Progress in Neurobiology</i> , <b>2017</b> , 152, 21-37	10.9	92
169	Glutamate and Gamma-Aminobutyric Acid Systems in the Pathophysiology of Major Depression and Antidepressant Response to Ketamine. <i>Biological Psychiatry</i> , <b>2017</b> , 81, 886-897	7.9	222
168	Investigational drugs in recent clinical trials for treatment-resistant depression. <i>Expert Review of Neurotherapeutics</i> , <b>2017</b> , 17, 593-609	4.3	46
167	Ketamine and Psychosis History: Antidepressant Efficacy and Psychotomimetic Effects Postinfusion. <i>Biological Psychiatry</i> , <b>2017</b> , 82, e35-e36	7.9	16
166	Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression. <i>Drugs</i> , <b>2017</b> , 77, 381-401	12.1	69
165	Anhedonia as a clinical correlate of suicidal thoughts in clinical ketamine trials. <i>Journal of Affective Disorders</i> , <b>2017</b> , 218, 195-200	6.6	55
164	Ketamine Mechanism of Action: Separating the Wheat from the Chaff. <i>Neuropsychopharmacology</i> , <b>2017</b> , 42, 368-369	8.7	11
163	Motor-Activity Markers of Circadian Timekeeping Are Related to Ketamine's Rapid Antidepressant Properties. <i>Biological Psychiatry</i> , <b>2017</b> , 82, 361-369	7.9	54
162	A Double-Blind, Placebo-Controlled, Pilot Study of Riluzole Monotherapy for Acute Bipolar Depression. <i>Journal of Clinical Psychopharmacology</i> , <b>2017</b> , 37, 355-358	1.7	22
161	Using Neuroimaging to Decipher the Mechanism of Action of Ketamine: A Pathway to Novel Therapeutics?. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , <b>2017</b> , 2, 549-551	3.4	

160	The antidepressant efficacy of subanesthetic-dose ketamine does not correlate with baseline subcortical volumes in a replication sample with major depressive disorder. <i>Journal of Psychopharmacology</i> , <b>2017</b> , 31, 1570-1577	4.6	10
159	Antisuicidal Response Following Ketamine Infusion Is Associated With Decreased Nighttime Wakefulness in Major Depressive Disorder and Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , <b>2017</b> , 78, 1068-1074	4.6	45
158	Synthesis and N-Methyl-d-aspartate (NMDA) Receptor Activity of Ketamine Metabolites. <i>Organic Letters</i> , <b>2017</b> , 19, 4572-4575	6.2	38
157	Altered interaction with environmental reinforcers in major depressive disorder: Relationship to anhedonia. <i>Behaviour Research and Therapy</i> , <b>2017</b> , 97, 170-177	5.2	8
156	Active suicidal ideation during clinical antidepressant trials. <i>Psychiatry Research</i> , <b>2017</b> , 257, 303-308	9.9	7
155	Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion. <i>Journal of Affective Disorders</i> , <b>2017</b> , 208, 560-566	6.6	32
154	Mood Therapeutics: Novel Pharmacological Approaches for Treating Depression. <i>Expert Review of Clinical Pharmacology</i> , <b>2017</b> , 10, 153-166	3.8	22
153	Sleep architecture parameters as a putative biomarker of suicidal ideation in treatment-resistant depression. <i>Journal of Affective Disorders</i> , <b>2017</b> , 208, 309-315	6.6	39
152	Genetic Studies on the Tripartite Glutamate Synapse in the Pathophysiology and Therapeutics of Mood Disorders. <i>Neuropsychopharmacology</i> , <b>2017</b> , 42, 787-800	8.7	26
151	Increased Activity or Energy as a Primary Criterion for the Diagnosis of Bipolar Mania in DSM-5: Findings From the STEP-BD Study. <i>American Journal of Psychiatry</i> , <b>2017</b> , 174, 70-76	11.9	18
150	Change in cytokine levels is not associated with rapid antidepressant response to ketamine in treatment-resistant depression. <i>Journal of Psychiatric Research</i> , <b>2017</b> , 84, 113-118	5.2	51
149	Reply to: Antidepressant Actions of Ketamine Versus Hydroxynorketamine. <i>Biological Psychiatry</i> , <b>2017</b> , 81, e69-e71	7.9	20
148	Case series: Antidepressant effects of low-affinity and low-trapping NMDA receptor antagonists did not predict response to ketamine in seven subjects. <i>Journal of Psychiatric Research</i> , <b>2017</b> , 86, 55-57	5.2	1
147	Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder. <i>Current Neuropsychopharmacology</i> , <b>2017</b> , 15, 57-70	7.6	63
146	Recognition of emotional facial expressions in anxious and nonanxious depression. <i>Comprehensive Psychiatry</i> , <b>2016</b> , 70, 1-8	7.3	13
145	Amygdala response to explicit sad face stimuli at baseline predicts antidepressant treatment response to scopolamine in major depressive disorder. <i>Psychiatry Research - Neuroimaging</i> , <b>2016</b> , 254, 67-73	2.9	22
144	Preliminary differences in resting state MEG functional connectivity pre- and post-ketamine in major depressive disorder. <i>Psychiatry Research - Neuroimaging</i> , <b>2016</b> , 254, 56-66	2.9	27
143	An assessment of the anti-fatigue effects of ketamine from a double-blind, placebo-controlled, crossover study in bipolar disorder. <i>Journal of Affective Disorders</i> , <b>2016</b> , 194, 115-9	6.6	21

142	Safety of research into severe and treatment-resistant mood disorders: analysis of outcome data from 12 years of clinical trials at the US National Institute of Mental Health. <i>Lancet Psychiatry</i> , <b>2016</b> , 3, 436-42	23.3	10
141	Potential Novel Treatments in Bipolar Depression. <i>Milestones in Drug Therapy</i> , <b>2016</b> , 259-285		
140	Nocturnal Wakefulness Is Associated With Next-Day Suicidal Ideation in Major Depressive Disorder and Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , <b>2016</b> , 77, 825-31	4.6	39
139	GSK-3: A key regulatory target for ketamine's rapid antidepressant effects mediated by enhanced AMPA to NMDA throughput. <i>Bipolar Disorders</i> , <b>2016</b> , 18, 702-705	3.8	13
138	NMDAR inhibition-independent antidepressant actions of ketamine metabolites. <i>Nature</i> , <b>2016</b> , 533, 481-4	50.4	903
137	Assessing measures of suicidal ideation in clinical trials with a rapid-acting antidepressant. <i>Journal of Psychiatric Research</i> , <b>2015</b> , 68, 68-73	5.2	39
136	Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review. <i>Therapeutic Advances in Chronic Disease</i> , <b>2015</b> , 6, 97-114	4.9	134
135	Neural correlates of change in major depressive disorder anhedonia following open-label ketamine. <i>Journal of Psychopharmacology</i> , <b>2015</b> , 29, 596-607	4.6	128
134	The Prodrug 4-Chlorokynurenine Causes Ketamine-Like Antidepressant Effects, but Not Side Effects, by NMDA/GlycineB-Site Inhibition. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2015</b> , 355, 76-85	4.7	77
133	Purinergic system dysfunction in mood disorders: a key target for developing improved therapeutics. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2015</b> , 57, 117-31	5.5	70
132	Shank3 as a potential biomarker of antidepressant response to ketamine and its neural correlates in bipolar depression. <i>Journal of Affective Disorders</i> , <b>2015</b> , 172, 307-11	6.6	19
131	Assessment of non-BDNF neurotrophins and GDNF levels after depression treatment with sertraline and transcranial direct current stimulation in a factorial, randomized, sham-controlled trial (SELECT-TDCS): an exploratory analysis. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2015</b> , 54, 81-6	5.5	24
130	D-serine plasma concentration is a potential biomarker of (R,S)-ketamine antidepressant response in subjects with treatment-resistant depression. <i>Psychopharmacology</i> , <b>2015</b> , 232, 399-409	4.7	52
129	Lithium and Valproate Levels Do Not Correlate with Ketamine's Antidepressant Efficacy in Treatment-Resistant Bipolar Depression. <i>Neural Plasticity</i> , <b>2015</b> , 2015, 858251	3.3	14
128	Potential Pathways Involved in the Rapid Antidepressant Effects of Nitrous Oxide. <i>Biological Psychiatry</i> , <b>2015</b> , 78, 2-4	7.9	8
127	Group differences in MEG-ICA derived resting state networks: Application to major depressive disorder. <i>NeuroImage</i> , <b>2015</b> , 118, 1-12	7.9	77
126	Ketamine for depression: evidence, challenges and promise. <i>World Psychiatry</i> , <b>2015</b> , 14, 348-50	14.4	33
125	Pretreatment Differences in BOLD Response to Emotional Faces Correlate with Antidepressant Response to Scopolamine. <i>International Journal of Neuropsychopharmacology</i> , <b>2015</b> , 18,	5.8	11

124	Novel Glutamatergic Treatments for Severe Mood Disorders. <i>Current Behavioral Neuroscience Reports</i> , <b>2015</b> , 2, 198-208	1.7	26
123	Development of a clinician-administered National Institutes of Health-Brief Fatigue Inventory: A measure of fatigue in the context of depressive disorders. <i>Journal of Psychiatric Research</i> , <b>2015</b> , 68, 99-105	5.2	6
122	Rating depression over brief time intervals with the Hamilton Depression Rating Scale: standard vs. abbreviated scales. <i>Journal of Psychiatric Research</i> , <b>2015</b> , 61, 40-5	5.2	5
121	A single infusion of ketamine improves depression scores in patients with anxious bipolar depression. <i>Bipolar Disorders</i> , <b>2015</b> , 17, 438-43	3.8	63
120	Neural correlates of suicidal ideation and its reduction in depression. <i>International Journal of Neuropsychopharmacology</i> , <b>2014</b> , 18,	5.8	34
119	Do the dissociative side effects of ketamine mediate its antidepressant effects?. <i>Journal of Affective Disorders</i> , <b>2014</b> , 159, 56-61	6.6	173
118	Neural correlates of rapid antidepressant response to ketamine in bipolar disorder. <i>Bipolar Disorders</i> , <b>2014</b> , 16, 119-28	3.8	59
117	Developing biomarkers in mood disorders research through the use of rapid-acting antidepressants. <i>Depression and Anxiety</i> , <b>2014</b> , 31, 297-307	8.4	39
116	Lithium increases nitric oxide levels in subjects with bipolar disorder during depressive episodes. <i>Journal of Psychiatric Research</i> , <b>2014</b> , 55, 96-100	5.2	20
115	Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder. <i>Journal of Neural Transmission</i> , <b>2014</b> , 121, 907-24	4.3	92
114	Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds. <i>Annual Review of Pharmacology and Toxicology</i> , <b>2014</b> , 54, 119-39	17.9	116
113	Glial abnormalities in substance use disorders and depression: does shared glutamatergic dysfunction contribute to comorbidity?. <i>World Journal of Biological Psychiatry</i> , <b>2014</b> , 15, 2-16	3.8	20
112	Riluzole likely lacks antidepressant efficacy in ketamine non-responders. <i>Journal of Psychiatric Research</i> , <b>2014</b> , 58, 197-9	5.2	17
111	12-week, placebo-controlled trial of add-on riluzole in the treatment of childhood-onset obsessive-compulsive disorder. <i>Neuropsychopharmacology</i> , <b>2014</b> , 39, 1453-9	8.7	54
110	Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety. <i>Journal of Psychiatric Research</i> , <b>2014</b> , 58, 161-6	5.2	173
109	Existing and novel biological therapeutics in suicide prevention. <i>American Journal of Preventive Medicine</i> , <b>2014</b> , 47, S195-203	6.1	62
108	Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder. <i>International Journal of Neuropsychopharmacology</i> , <b>2014</b> , 18,	5.8	27
107	Biomarkers in mood disorders research: developing new and improved therapeutics. <i>Revista De Psiquiatria Clinica</i> , <b>2014</b> , 41, 131-134	0.8	6

106	Multiple levels of impaired neural plasticity and cellular resilience in bipolar disorder: developing treatments using an integrated translational approach. <i>World Journal of Biological Psychiatry</i> , <b>2014</b> , 15, 84-95	3.8	42
105	Increased fear-potentiated startle in major depressive disorder patients with lifetime history of suicide attempt. <i>Journal of Affective Disorders</i> , <b>2014</b> , 162, 34-8	6.6	26
104	Clinical predictors of ketamine response in treatment-resistant major depression. <i>Journal of Clinical Psychiatry</i> , <b>2014</b> , 75, e417-23	4.6	100
103	Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine. <i>Journal of Clinical Psychiatry</i> , <b>2014</b> , 75, e932-8	4.6	69
102	Pharmacologic treatment of dimensional anxious depression: a review. <i>primary care companion for CNS disorders, The</i> , <b>2014</b> , 16,	1.2	23
101	Experimental Pharmacologic Approaches for the Reduction of Suicidal Ideation and Behavior <b>2014</b> , 209-221		
100	Automated subcortical segmentation using FIRST: test-retest reliability, interscanner reliability, and comparison to manual segmentation. <i>Human Brain Mapping</i> , <b>2013</b> , 34, 2313-29	5.9	87
99	NEUROBIOLOGICAL ASPECTS OF SUICIDE AND SUICIDE ATTEMPTS IN BIPOLAR DISORDER. <i>Translational Neuroscience</i> , <b>2013</b> , 4,	1.2	28
98	Acute stress symptoms do not worsen in posttraumatic stress disorder and abuse with a single subanesthetic dose of ketamine. <i>Biological Psychiatry</i> , <b>2013</b> , 73, e37-8	7.9	13
97	Baseline delta sleep ratio predicts acute ketamine mood response in major depressive disorder. <i>Journal of Affective Disorders</i> , <b>2013</b> , 145, 115-9	6.6	50
96	Ketamine, sleep, and depression: current status and new questions. <i>Current Psychiatry Reports</i> , <b>2013</b> , 15, 394	9.1	51
95	A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression. <i>Biological Psychiatry</i> , <b>2013</b> , 74, 257-64	7.9	178
94	Ketamine regulates the presynaptic release machinery in the hippocampus. <i>Journal of Psychiatric Research</i> , <b>2013</b> , 47, 892-9	5.2	39
93	Sub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in $\alpha$ 7 nicotinic acetylcholine receptors. <i>European Journal of Pharmacology</i> , <b>2013</b> , 698, 228-34	5.3	116
92	Human biomarkers of rapid antidepressant effects. <i>Biological Psychiatry</i> , <b>2013</b> , 73, 1142-55	7.9	79
91	Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder. <i>International Journal of Neuropsychopharmacology</i> , <b>2013</b> , 16, 301-11	5.8	141
90	Neural correlates of rapid antidepressant response to ketamine in treatment-resistant unipolar depression: a preliminary positron emission tomography study. <i>Biological Psychiatry</i> , <b>2013</b> , 73, 1213-21	7.9	121
89	Second messenger/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action, part I: major depressive disorder. <i>CNS Spectrums</i> , <b>2013</b> , 18, 231-41	1.8	31

88	Subanesthetic dose ketamine does not induce an affective switch in three independent samples of treatment-resistant major depression. <i>Biological Psychiatry</i> , <b>2013</b> , 74, e23-4	7.9	29
87	Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review. <i>Biological Psychiatry</i> , <b>2013</b> , 73, 1156-63	7.9	123
86	Potential of pretreatment neural activity in the visual cortex during emotional processing to predict treatment response to scopolamine in major depressive disorder. <i>JAMA Psychiatry</i> , <b>2013</b> , 70, 280-90	14.5	69
85	Second messenger/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action, part II: bipolar disorder. <i>CNS Spectrums</i> , <b>2013</b> , 18, 242-51	1.8	12
84	Mood stabilizer treatment increases serotonin type 1A receptor binding in bipolar depression. <i>Journal of Psychopharmacology</i> , <b>2013</b> , 27, 894-902	4.6	17
83	Current status of ketamine and related compounds for depression. <i>Journal of Clinical Psychiatry</i> , <b>2013</b> , 74, 516-7	4.6	25
82	Novel glutamatergic agents for major depressive disorder and bipolar disorder. <i>Pharmacology Biochemistry and Behavior</i> , <b>2012</b> , 100, 678-87	3.9	65
81	Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression. <i>British Journal of Clinical Pharmacology</i> , <b>2012</b> , 74, 304-14	3.8	86
80	Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression. <i>Bipolar Disorders</i> , <b>2012</b> , 14, 880-7	3.8	52
79	Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression. <i>Biological Psychiatry</i> , <b>2012</b> , 72, 555-61	7.9	135
78	Baseline mood-state measures as predictors of antidepressant response to scopolamine. <i>Psychiatry Research</i> , <b>2012</b> , 196, 62-7	9.9	26
77	Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date. <i>Drugs</i> , <b>2012</b> , 72, 1313-33	12.1	143
76	Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. <i>Biological Psychiatry</i> , <b>2012</b> , 71, 939-46	7.9	576
75	Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression. <i>Biological Psychiatry</i> , <b>2012</b> , 72, 331-8	7.9	187
74	Ketamine for depression: where do we go from here?. <i>Biological Psychiatry</i> , <b>2012</b> , 72, 537-47	7.9	283
73	Effects of lithium on oxidative stress parameters in healthy subjects. <i>Molecular Medicine Reports</i> , <b>2012</b> , 5, 680-2	2.9	79
72	Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. <i>Neuropsychopharmacology</i> , <b>2012</b> , 37, 1526-33	8.7	225
71	A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. <i>Journal of Clinical Psychopharmacology</i> , <b>2012</b> , 32, 551-7	1.7	152

70	Acute D-serine treatment produces antidepressant-like effects in rodents. <i>International Journal of Neuropsychopharmacology</i> , <b>2012</b> , 15, 1135-48	5.8	61
69	An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression. <i>International Journal of Neuropsychopharmacology</i> , <b>2012</b> , 15, 1063-72	5.8	65
68	Rapid antidepressant changes with sleep deprivation in major depressive disorder are associated with changes in vascular endothelial growth factor (VEGF): a pilot study. <i>Brain Research Bulletin</i> , <b>2011</b> , 86, 129-33	3.9	32
67	Rapid decrease in depressive symptoms with an N-methyl-D-aspartate antagonist in ECT-resistant major depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2011</b> , 35, 1155-9	5.5	135
66	Proof of concept trials in bipolar disorder and major depressive disorder: a translational perspective in the search for improved treatments. <i>Depression and Anxiety</i> , <b>2011</b> , 28, 267-81	8.4	20
65	Potential novel therapeutics for bipolar disorders. <i>Current Topics in Behavioral Neurosciences</i> , <b>2011</b> , 5, 303-29	3.4	2
64	Bipolar disorder: a neurobiological synthesis. <i>Current Topics in Behavioral Neurosciences</i> , <b>2011</b> , 5, 331-40	3.4	5
63	New therapeutic targets for mood disorders. <i>Scientific World Journal, The</i> , <b>2010</b> , 10, 713-26	2.2	45
62	The Timing of Antidepressant Effects: A Comparison of Diverse Pharmacological and Somatic Treatments. <i>Pharmaceuticals</i> , <b>2010</b> , 3, 19-41	5.2	108
61	Novel insights into lithium's mechanism of action: neurotrophic and neuroprotective effects. <i>Neuropsychobiology</i> , <b>2010</b> , 62, 50-60	4	149
60	A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. <i>Archives of General Psychiatry</i> , <b>2010</b> , 67, 793-802		702
59	Level of response and safety of pharmacological monotherapy in the treatment of acute bipolar I disorder phases: a systematic review and meta-analysis. <i>International Journal of Neuropsychopharmacology</i> , <b>2010</b> , 13, 813-32	5.8	34
58	Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. <i>Neuropsychopharmacology</i> , <b>2010</b> , 35, 1415-22	8.7	175
57	Magnetic resonance spectroscopy studies of the glutamatergic system in mood disorders: a pathway to diagnosis, novel therapeutics, and personalized medicine?. <i>Biological Psychiatry</i> , <b>2010</b> , 68, 780-2	7.9	17
56	Increased uric acid levels in drug-naïve subjects with bipolar disorder during a first manic episode. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2010</b> , 34, 819-21	5.5	52
55	Novel Therapeutic Strategies for Bipolar Disorder <b>2010</b> , 395-411		
54	Perception of facial emotion in adults with bipolar or unipolar depression and controls. <i>Journal of Psychiatric Research</i> , <b>2010</b> , 44, 1229-35	5.2	51
53	Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. <i>Journal of Clinical Psychiatry</i> , <b>2010</b> , 71, 1605-11	4.6	409

52	The neurobiology of the switch process in bipolar disorder: a review. <i>Journal of Clinical Psychiatry</i> , <b>2010</b> , 71, 1488-501	4.6	133
51	The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders. <i>Neuroscientist</i> , <b>2009</b> , 15, 525-39	7.6	132
50	Ketamine and the next generation of antidepressants with a rapid onset of action. <i>Pharmacology &amp; Therapeutics</i> , <b>2009</b> , 123, 143-50	13.9	209
49	The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis. <i>Bipolar Disorders</i> , <b>2009</b> , 11 Suppl 2, 92-109	3.8	229
48	Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. <i>Biological Psychiatry</i> , <b>2009</b> , 65, 289-99	7.9	219
47	Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. <i>Biological Psychiatry</i> , <b>2009</b> , 65, 181-4	7.9	149
46	Protein kinase C inhibitors: rationale for use and potential in the treatment of bipolar disorder. <i>CNS Drugs</i> , <b>2009</b> , 23, 569-82	6.7	94
45	Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders. <i>Current Pharmaceutical Design</i> , <b>2009</b> , 15, 1595-611	3.3	96
44	Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist. <i>Journal of Clinical Psychiatry</i> , <b>2009</b> , 70, 1662-6	4.6	107
43	Potential novel treatments for bipolar depression <b>2009</b> , 191-209		
42	Early intervention in bipolar disorder, part II: therapeutics. <i>Microbial Biotechnology</i> , <b>2008</b> , 2, 136-46	3.3	16
41	Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. <i>Nature Reviews Drug Discovery</i> , <b>2008</b> , 7, 426-37	64.1	633
40	Early intervention in bipolar disorder, part I: clinical and imaging findings. <i>Microbial Biotechnology</i> , <b>2008</b> , 2, 122-35	3.3	17
39	A comparison of cognitive functioning in medicated and unmedicated subjects with bipolar depression. <i>Bipolar Disorders</i> , <b>2008</b> , 10, 806-15	3.8	70
38	Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. <i>Biological Psychiatry</i> , <b>2008</b> , 63, 349-52	7.9	861
37	The role of AMPA receptor modulation in the treatment of neuropsychiatric diseases. <i>Experimental Neurology</i> , <b>2008</b> , 211, 7-10	5.7	75
36	Riluzole in psychiatry: a systematic review of the literature. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2008</b> , 4, 1223-34	5.5	64
35	Neurobiology of bipolar disorder. <i>Expert Review of Neurotherapeutics</i> , <b>2008</b> , 8, 93-110	4.3	50

34	A review of the preclinical and clinical evidence for protein kinase C as a target for drug development for bipolar disorder. <i>Current Psychiatry Reports</i> , <b>2008</b> , 10, 510-9	9.1	44
33	Bipolar disorder: candidate drug targets. <i>Mount Sinai Journal of Medicine</i> , <b>2008</b> , 75, 226-47		42
32	Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. <i>Journal of Clinical Psychiatry</i> , <b>2008</b> , 69, 946-58	4.6	139
31	A double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania. <i>Journal of Clinical Psychiatry</i> , <b>2008</b> , 69, 1237-45	4.6	92
30	Searching for Rational Anti-N-methyl-D-aspartate Treatment for Depression Reply. <i>Archives of General Psychiatry</i> , <b>2007</b> , 64, 1100		8
29	Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. <i>Bipolar Disorders</i> , <b>2007</b> , 9, 561-70	3.8	170
28	The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. <i>Current Psychiatry Reports</i> , <b>2007</b> , 9, 467-74	9.1	175
27	The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. <i>Neuropsychopharmacology</i> , <b>2007</b> , 32, 793-802	8.7	178
26	A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. <i>Archives of General Psychiatry</i> , <b>2006</b> , 63, 856-64		2439
25	Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. <i>Biological Psychiatry</i> , <b>2006</b> , 59, 1006-20	7.9	209
24	Enhancing AMPA to NMDA throughput as a convergent mechanism for antidepressant action. <i>Drug Discovery Today: Therapeutic Strategies</i> , <b>2006</b> , 3, 519-526		39
23	Identification of molecular mechanisms underlying mood stabilization through genome-wide gene expression profiling. <i>International Journal of Neuropsychopharmacology</i> , <b>2006</b> , 9, 263-6	5.8	3
22	Neural circuitry and neuroplasticity in mood disorders: insights for novel therapeutic targets. <i>NeuroRx</i> , <b>2006</b> , 3, 22-41		111
21	The acute treatment of bipolar depression: Historically relevant and recent controlled trials. <i>Current Psychosis &amp; Therapeutics Reports</i> , <b>2006</b> , 4, 151-158		
20	Emerging Novel Treatments for Severe Mood Disorders Involving Cellular Plasticity Cascades. <i>Current Psychosis &amp; Therapeutics Reports</i> , <b>2006</b> , 4, 181-190		1
19	A double-blind, placebo-controlled study of memantine in the treatment of major depression. <i>American Journal of Psychiatry</i> , <b>2006</b> , 163, 153-5	11.9	282
18	An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. <i>Biological Psychiatry</i> , <b>2005</b> , 57, 430-2	7.9	207
17	Molecular mechanisms of bipolar disorder. <i>Drug Discovery Today Disease Mechanisms</i> , <b>2005</b> , 2, 435-445		2

16	Mood-congruent bias in affective go/no-go performance of unmedicated patients with major depressive disorder. <i>American Journal of Psychiatry</i> , <b>2005</b> , 162, 2171-3	11.9	157
15	An open-label trial of riluzole in patients with treatment-resistant major depression. <i>American Journal of Psychiatry</i> , <b>2004</b> , 161, 171-4	11.9	289
14	Case report: Successful riluzole augmentation therapy in treatment-resistant bipolar depression following the development of rash with lamotrigine. <i>Psychopharmacology</i> , <b>2004</b> , 173, 227-8	4.7	21
13	Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. <i>Biological Psychiatry</i> , <b>2004</b> , 56, 54-60	7.9	268
12	Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. <i>British Journal of Psychiatry</i> , <b>2004</b> , 184, 337-45	5.4	250
11	Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients. <i>American Journal of Psychiatry</i> , <b>2004</b> , 161, 169-71	11.9	100
10	Glycogen Synthase Kinase-3. <i>Journal of Clinical Psychiatry</i> , <b>2004</b> , 65, 10-21	4.6	138
9	The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence. <i>American Journal of Psychiatry</i> , <b>2003</b> , 160, 2099-107	11.9	359
8	Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system. <i>Annals of the New York Academy of Sciences</i> , <b>2003</b> , 1003, 273-91	6.5	143
7	Combination treatment in bipolar disorder: a review of controlled trials. <i>Bipolar Disorders</i> , <b>2003</b> , 5, 217-25	5.8	44
6	Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. <i>Biological Psychiatry</i> , <b>2003</b> , 53, 707-42	7.9	412
5	Timing is everything: does the robust upregulation of noradrenergically regulated plasticity genes underlie the rapid antidepressant effects of sleep deprivation?. <i>Biological Psychiatry</i> , <b>2002</b> , 52, 921-6	7.9	39
4	Modulators of the glutamatergic system: implications for the development of improved therapeutics in mood disorders. <i>Psychopharmacology Bulletin</i> , <b>2002</b> , 36, 35-83	0.9	80
3	Cycling into depression from a first episode of mania: a case-comparison study. <i>American Journal of Psychiatry</i> , <b>2001</b> , 158, 1524-6	11.9	16
2	A wake-up call - revealing the oversight of sleep physiology and related translational discrepancies in studies of rapid-acting antidepressants		1
1	Novel Therapeutic Approaches for Treating Bipolar Disorder	423-445	